SRDX — Surmodics, Inc.

Summary of Surmodics (SRDX) Q2 2024 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: Increased 18% year-over-year to $32 million; 19% growth excluding SurVeil drug-coated balloon (DCB) license fee revenue.
• Medical Device Segment: Revenue grew 26% to $24.8 million, with product sales up 40% year-over-year.
• In Vitro Diagnostics (IVD) Segment: Revenue decreased 5% to $7.1 million.
• GAAP Net Income: $250,000 or $0.02 per diluted share, compared to a net loss of $7.7 million in the prior year.
• Adjusted EBITDA: Increased to $4.8 million from a loss of $1.5 million year-over-year.
• Cash Flow: Generated $7.4 million from operations, bolstered by a $3.4 million tax refund.
• Cash Position: Ended the quarter with $40.9 million in cash and investments.

2. Strategic Updates and Business Highlights

• Product Launches: Successful commercialization of four new products including SurVeil DCB, Pounce Venous, Pounce Low Profile, and Preside coating.
• Sales Performance: Strong demand for SurVeil DCB and Pounce thrombectomy products, with consistent monthly orders from Abbott.
• Market Expansion: Pounce Venous transitioned to full commercial launch, showing promising clinical performance.
• R&D Focus: Continued investment in vascular interventions and performance coatings to maintain competitive advantage.

3. Forward Guidance and Outlook

• Fiscal 2024 Revenue Guidance: Updated to $122 million to $124 million (8% to 6% decrease from prior year); $118 million to $120 million excluding SurVeil DCB revenue (15% to 17% increase).
• GAAP Loss Per Share Guidance: Expected to range from a loss of $0.90 to $0.70.
• Product Revenue Expectations: Anticipate at least $15.5 million from SurVeil, Pounce, and Sublime products.
• Third Quarter Revenue Guidance: Expected to range from $29.5 million to $30.5 million, reflecting a significant decrease due to the prior year’s SurVeil DCB license fee revenue.

4. Bad News, Challenges, or Points of Concern

• Declining IVD Revenue: The IVD segment continues to face challenges with a 5% revenue decline, attributed to lower substrate product sales.
• SurVeil DCB License Fee Revenue: Expected to drop significantly to approximately $4 million in fiscal 2024 from $29.6 million in fiscal 2023.
• Product Gross Margin Pressures: Product gross margin was 60.8%, down from 62.6% year-over-year, impacted by production inefficiencies as new products ramp up.
• Market Competition: Concerns about Abbott's competitive positioning with new product launches in the same market.

5. Notable Q&A Insights

• Total Addressable Market (TAM): Management indicated that the TAM for SurVeil is substantial, potentially exceeding $1 billion, driven by the FDA's removal of the label warning on paclitaxel.
• Abbott Partnership: Abbott is focused on establishing a strong U.S. market presence before considering international expansion for SurVeil.
• R&D Spending: While R&D spending has historically been around 50% of revenue, it is expected to decrease as revenue grows, with a focus on maintaining a balanced pipeline.
• Profit Sharing with Abbott: Profit-sharing calculations are based on unit shipments and sales, with no significant changes expected in the near term.

Overall, Surmodics reported a strong quarter with significant revenue growth and product launches, but faces challenges in its IVD segment and the upcoming decrease in SurVeil DCB license fee revenue. The company remains optimistic about its growth trajectory and strategic initiatives.